

Poly ADP-ribose polymerase (PARP) Inhibitors for Ovarian Cancer

Key Stakeholder Organizations

ICER has identified the following organizations as key stakeholders for its upcoming report on poly ADP-ribose polymerase (PARP) inhibitors for Ovarian Cancer. ICER will invite input from the following organizations, and welcomes suggestions from the broader community on additional organizations to add to this list. ICER often receives comments from individual patients and clinicians, and invites the public to submit recommendations for key stakeholders in these categories.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- American Cancer Society
- AstraZeneca
- Clovis Oncology
- Facing Our Risk of Cancer Empowered (FORCE)
- Friends of Cancer Research
- Foundation for Women's Cancer
- Minnesota Ovarian Cancer Alliance
- National Ovarian Cancer Coalition
- Omeda RX
- Ovarian Cancer Institute
- Ovarian Cancer Research Fund Alliance
- Prime Therapeutics
- Research Advocacy Network
- Rivkin Center for Ovarian Cancer
- Society of Gynecologic Oncology
- Tesaro, Inc.